Browse NLGN3

Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cell junction, synapse Note=Detected at both glutamatergic and GABAergic synapses.
Domain PF00135 Carboxylesterase family
Function

Cell surface protein involved in cell-cell-interactions via its interactions with neurexin family members. Plays a role in synapse function and synaptic signal transmission, and may mediate its effects by clustering other synaptic proteins. May promote the initial formation of synapses, but is not essential for this. May also play a role in glia-glia or glia-neuron interactions in the developing peripheral nervous system (By similarity).

> Gene Ontology
 
Biological Process GO:0001941 postsynaptic membrane organization
GO:0002087 regulation of respiratory gaseous exchange by neurological system process
GO:0003016 respiratory system process
GO:0006898 receptor-mediated endocytosis
GO:0007158 neuron cell-cell adhesion
GO:0007215 glutamate receptor signaling pathway
GO:0007270 neuron-neuron synaptic transmission
GO:0007409 axonogenesis
GO:0007416 synapse assembly
GO:0007585 respiratory gaseous exchange
GO:0007611 learning or memory
GO:0007612 learning
GO:0007632 visual behavior
GO:0008306 associative learning
GO:0008542 visual learning
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0010001 glial cell differentiation
GO:0010469 regulation of receptor activity
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016049 cell growth
GO:0016358 dendrite development
GO:0022604 regulation of cell morphogenesis
GO:0022898 regulation of transmembrane transporter activity
GO:0030534 adult behavior
GO:0031345 negative regulation of cell projection organization
GO:0032409 regulation of transporter activity
GO:0032411 positive regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032414 positive regulation of ion transmembrane transporter activity
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035176 social behavior
GO:0035249 synaptic transmission, glutamatergic
GO:0042063 gliogenesis
GO:0042391 regulation of membrane potential
GO:0043270 positive regulation of ion transport
GO:0043576 regulation of respiratory gaseous exchange
GO:0044057 regulation of system process
GO:0044065 regulation of respiratory system process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044091 membrane biogenesis
GO:0044708 single-organism behavior
GO:0045665 negative regulation of neuron differentiation
GO:0048167 regulation of synaptic plasticity
GO:0048588 developmental cell growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048709 oligodendrocyte differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050774 negative regulation of dendrite morphogenesis
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0050890 cognition
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051703 intraspecies interaction between organisms
GO:0051705 multi-organism behavior
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0051963 regulation of synapse assembly
GO:0051965 positive regulation of synapse assembly
GO:0051966 regulation of synaptic transmission, glutamatergic
GO:0051968 positive regulation of synaptic transmission, glutamatergic
GO:0060024 rhythmic synaptic transmission
GO:0060078 regulation of postsynaptic membrane potential
GO:0060079 excitatory postsynaptic potential
GO:0060080 inhibitory postsynaptic potential
GO:0060291 long-term synaptic potentiation
GO:0060560 developmental growth involved in morphogenesis
GO:0060996 dendritic spine development
GO:0060997 dendritic spine morphogenesis
GO:0060998 regulation of dendritic spine development
GO:0061000 negative regulation of dendritic spine development
GO:0061001 regulation of dendritic spine morphogenesis
GO:0061002 negative regulation of dendritic spine morphogenesis
GO:0061564 axon development
GO:0071625 vocalization behavior
GO:0071709 membrane assembly
GO:0072553 terminal button organization
GO:0090394 negative regulation of excitatory postsynaptic potential
GO:0097061 dendritic spine organization
GO:0097090 presynaptic membrane organization
GO:0097091 synaptic vesicle clustering
GO:0097104 postsynaptic membrane assembly
GO:0097105 presynaptic membrane assembly
GO:0097479 synaptic vesicle localization
GO:0098815 modulation of excitatory postsynaptic potential
GO:0099054 presynapse assembly
GO:0099068 postsynapse assembly
GO:0099504 synaptic vesicle cycle
GO:0099565 chemical synaptic transmission, postsynaptic
GO:0099601 regulation of neurotransmitter receptor activity
GO:1900271 regulation of long-term synaptic potentiation
GO:1900449 regulation of glutamate receptor signaling pathway
GO:1900451 positive regulation of glutamate receptor signaling pathway
GO:1990138 neuron projection extension
GO:2000171 negative regulation of dendrite development
GO:2000273 positive regulation of receptor activity
GO:2000310 regulation of N-methyl-D-aspartate selective glutamate receptor activity
GO:2000311 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity
GO:2000331 regulation of terminal button organization
GO:2000463 positive regulation of excitatory postsynaptic potential
GO:2000807 regulation of synaptic vesicle clustering
GO:2000809 positive regulation of synaptic vesicle clustering
GO:2000969 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity
Molecular Function GO:0042043 neurexin family protein binding
GO:0050839 cell adhesion molecule binding
GO:0052689 carboxylic ester hydrolase activity
GO:0097110 scaffold protein binding
Cellular Component GO:0030139 endocytic vesicle
GO:0060076 excitatory synapse
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-112316: Neuronal System
R-HSA-6794362: Protein-protein interactions at synapses
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NLGN3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NLGN3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NLGN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6420.135
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7650.288
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5490.375
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0850.798
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1940.903
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0430.984
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2670.524
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4340.552
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0130.986
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1520.733
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6240.314
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0740.612
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NLGN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLGN3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLGN3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLGN3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLGN3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NLGN3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NLGN3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNLGN3
Nameneuroligin 3
Aliases HNL3; KIAA1480; ASPGX1; AUTSX1; gliotactin homolog; Neuroligin-3
Chromosomal LocationXq13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NLGN3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.